The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration

American Journal of Ophthalmology

Volumn 158, Issue 4, 2014, Pages 769-779.e2

  Jung, Jesse J ^a,b,c,d   Chen, Christine Y ^b,c,e,f   Mrejen, Sarah ^b,c   Gallego Pinazo, Roberto ^a,g   Xu, Luna ^h   Marsiglia, Marcela ^b,c,d   Boddu, Sucharita ^a   Freund, K Bailey ^a,b,c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^c EAR AND THROAT HOSPITAL   (United States)

^d New York Presbyterian Hospital   (United States)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h NEW YORK EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AFRICAN AMERICAN; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; ASIAN; CAUCASIAN; COHORT ANALYSIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODAL IMAGING; NEOVASCULAR AGE RELATED MACULAR EGENERATION; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA DISEASE; RETINAL ANGIOMATOUS PROLIFERATION; RETROSPECTIVE STUDY; SMOKING; SUBRETINAL NEOVASCULARIZATION; CLASSIFICATION; COMPARATIVE STUDY; DRUG ANTAGONISM; EXUDATIVE MACULAR DEGENERATION; INCIDENCE; VERY ELDERLY; VISUAL ACUITY;

AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84908506258     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.07.006     Document Type: Article

References (58)

1. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-572.
2. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102(11):1640-1642.
3. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109(9):1220-1231.
4. Treatment of Age-related Macular Degeneration with Photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117(10):1329-1345.
5. Verteporfin in Photodynamic therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131(5):541-560.
6. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med 2004;351(27): 2805-2816.
7. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113(3):363-372.
8. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-1908.
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431.
10. Brown DM, Kaser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-1444.
11. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-2548.
12. Spaide RF, Curcio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. Retina 2011;31(8):1609-1619.
13. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina 2010;30(9):1333-1349.
14. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29(10):1424-1431.
15. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990; 10(1):1-8.
16. Yannuzzi LA, Negrão S, lida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21(5):416-434.
17. Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology 2000;107(4):742-753.
18. Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: The expanded spectrum of retinal angiomatous proliferation. Retina 2008;28(2):201-211.
19. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina 2008;28(3):375-384.
20. Grossniklaus HE, Gass JDM. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998;126(1): 59-69.
21. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109(9):1242-1257.
22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
23. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol 1987;105(2):209-213.
24. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Amer J Ophthalmol 1993;115(6):786-791.
25. Moisseiev J, Alhalel A, Masuri R, Treister G. The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol 1995;113(2):185-189.
26. Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features at the early stage of exudative age related macular degeneration. Br J Ophthalmol 2002;86(6): 663-669.
27. George S, Cooke C, Chakravarthy U. Exudative AMD subtypes and eligibility for treatment with ranibizumab. Eye 2010;25(7):1247-1251.
28. Cohen SY, Creuzot-Garcher C, Darmon J, et al. Types of choroidal neovascularization in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 2007; 91(9):1173-1176.
29. Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol 2007;245(10):1441-1445.
30. Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular agerelated macular degeneration. Ophthalmology 2004;111(2): 250-255.
31. Mrejen S, Sarraf D, Mukkamala SK, Freund KB. Multimodal imaging of pigment epithelial detachment: A guide to evaluation. Retina 2013;33(9):1735-1762.
32. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994;118(3): 285-298.
33. Querques G, Souied EH, Freund KB. Multimodal imaging of early stage 1 type 3 neovasculariation with simultaneous eyetracked spectral-domain optical coherence tomography and high-speed real-time angiography. Retina 2013;33(9): 1881-1887.
34. Sulzbacher F, Kiss C, Munk M, Deak G, Sacu S, Schmidt- Erfurth U. Diagnostic evaluation of type 2 (classic) choroidal neovascularization: optical coherence tomography, indocyanine green angiography, and fluorescein angiography. Am J Ophthalmol 2011;152(5):799-806.
35. dell'Omo R, Cassetta M, dell'Omo E, et al. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. Am J Ophthalmol 2012;153(1):155-161.
36. Fung AT, Yannuzzi LA, Freund KB. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina 2012;32(9):1829-1837.
37. Querques G, Querques L, Leveziel N, Bandello F, Souied EH. Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy. J Fr Ophtalmol 2013;36(1):e1-e4.
38. Hirami Y, Mandai M, Takahshi M, Teramukai S, Tada H, Yoshimura N. Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration. Jpn J Ophthalmol 2009;53(4):396-407.
39. Liakopoulos S, Ongchin S, Bansal A, et al. Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49(11):5048-5054.
40. Gross NS, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 2005;25(6):713-718.
41. Maruko I, Ida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144(1):15-22.
42. Sawa M, Ueno C, Gomi F, Nishida K. Incidence and characteristics of neovascularization in fellow eyes of Japanese patients with unilateral retinal angiomatous proliferation. Retina 2014;34(4):761-767.
43. ClinicalTrials.gov. A phase 3 safety and efficacy study of FovistaTM (E10030) intravitreous administration in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy. ClinicalTrials.gov Identifier NCT01940887. Available at http://clinicaltrials.gov/ct2/show/NCT01940887. Accessed February 23, 2014.
44. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report No. 2. Arch Ophthalmol 2003;121(9):1253-1268.
45. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136(3):407-418.
46. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004;137(3):496-503.
47. Friedman SM, Margo CE. Choroidal neovascular membranes: reproducibility of angiographic interpretation. Am J Ophthalmol 2000;130(6):839-841.
48. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAPstudy). Ophthalmology 2003;110(2):400-405.
49. Garg A, Oll M, Yzer S, et al. Reticular pseudodrusen in early age-related macular degeneration is associated with choroidal thinning. Invest Ophthalmol Vis Sci 2013;54(10): 7075-7081.
50. Spaide RF. Outer retinal atrophy after regression of subretinal drusenoid deposits as a newly recognized form of late age-related macular degeneration. Retina 2013;33(9): 1800-1808.
51. DeAngelis MM, Ji F, Kim IK, et al. Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. Arch Ophthalmol 2007;125(1):49-54.
52. Hughes AE, Orr N, Patterson C, et al. Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking. PloS Med 2007;4(12):e355.
53. Tamakoshi A, Yuzawa M, Matsui M, Uyama M, Fuijiwara NK, Ohno Y. Smoking and neovascular form of age related macular degeneration in late middle aged males: findings from a case-control study in Japan. Research committee on chorioretinal degenerations. Br J Ophthalmol 1997; 81(10):901-904.
54. Joachim N, Mitchell P, Kifley A, Rochtchina E, Hong T, Wang JJ. Incidence and progression of geographic atrophy: observations from a population-based cohort. Ophthalmology 2013;120(10):2042-2050.
55. Comparison of Age-relatedMacular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration two-year results. Ophthalmology 2012;119(7):1388-1398.
56. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: A critical analysis of literature. Eye 2010;24(5): 816-824.
57. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120(1):122-129.
58. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121(1): 150-161.